

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO "IMPORTANT INFORMATION" IN THE END OF THIS PRESS RELEASE.

## IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received

IRLAB Therapeutics AB ("IRLAB" or the "Company") has prepared an information document (the "Information Document") in connection with the rights issue of ordinary shares of series A which the Board of Directors, conditional upon subsequent approval by an extraordinary general meeting and amendment of the articles of association, resolved on 5 May 2026 (the "Rights Issue"). The extraordinary general meeting on 5 June 2026 approved the Board of Directors' resolution on the Rights Issue and amendment of the articles of association, which was announced earlier today. The Information Document is available on the Company's website, [www.irlab.se](http://www.irlab.se). The Information Document will also be made available on Aqurat Fondkommission AB's website, [www.aqurat.se](http://www.aqurat.se). IRLAB further announces that the Company has received additional subscription undertakings of a total of approximately SEK 1.8 million, of which the majority were previously subscription intentions, and in aggregate the subscription undertakings received amount to approximately SEK 56.8 million, corresponding to approximately 84 percent of the Rights Issue. Of previously communicated subscription intentions, one subscription intention of approximately SEK 4.9 million remains, corresponding to approximately 7.2 percent of the Rights Issue. In total, the Rights Issue is thus covered to approximately 91 percent through subscription undertakings and subscription intentions.

On 5 May 2026, the Board of Directors of the Company resolved, conditional upon subsequent approval by an extraordinary general meeting and amendment of the articles of association, to carry out a rights issue of ordinary shares of series A of a maximum of approximately SEK 68 million with preferential rights for existing shareholders. In addition to the Rights Issue, conditional upon the general meeting's subsequent approval and resolution on amendment of the articles of association, the Board of Directors resolved on an overallotment issue of ordinary shares of

series A with deviation from the shareholders' preferential rights of a maximum of approximately SEK 33.8 million (the "**Overallotment Issue**"). The extraordinary general meeting on 5 June 2026 resolved to approve the Board of Directors' resolution on the Rights Issue and the Overallotment Issue as well as amendment of the articles of association. Complete information, terms and conditions regarding the Rights Issue are set out in the Information Document. The Information Document is available on IRLAB's website, [www.irlab.se](http://www.irlab.se), and will also be made available on Aqurat Fondkommission AB's website, [www.aqurat.se](http://www.aqurat.se).

### The Information Document

In connection with the Rights Issue, the Company has prepared the Information Document in accordance with Article 1.4 db) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended (the "**Prospectus Regulation**"). The Information Document has been prepared in accordance with the requirements of Annex IX of the Prospectus Regulation. The Information Document has been registered with the Swedish Financial Supervisory Authority, but the Swedish Financial Supervisory Authority has not reviewed or approved the Information Document. The Information Document is only available in Swedish.

### Indicative time plan

The following time plan for the Rights Issue is preliminary and subject to change.

|  |  |
|--|--|
| Last day of trading in the series A share including subscription rights  | 5 June 2026  |
| First day of trading in the series A share excluding subscription rights | 8 June 2026  |
| Record date for the Rights Issue   | 9 June 2026  |
| Trading in subscription rights   | 11 – 22 June 2026  |
| Subscription period  | 11 – 25 June 2026  |
| Trading in paid subscribed shares (BTA)                                  | 11 June 2026 up to and including approximately week 28, 2026 |
| Expected day for announcement of the outcome                             | 29 June 2026   |

## Advisers

MAQS Advokatbyrå AB is legal advisor and Zonda Partners AB acts as financial advisor to the Company in connection with the Rights Issue. Aqurat Fondkommission AB is issuing agent in connection with the Rights Issue.

## For more information

Kristina Torfgård, CEO

Phone: +46 730 60 70 99

E-mail: [kristina.torfgard@irlab.se](mailto:kristina.torfgard@irlab.se)

Gustaf Albèrt, CFO

Phone: +46 709 168 302

E-mail: [gustaf.albert@irlab.se](mailto:gustaf.albert@irlab.se)

## About IRLAB

IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase Ib. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit [www.irlab.se](http://www.irlab.se).

## Important information

The publication, announcement, or distribution of this press release may, in certain jurisdictions, be subject to restrictions by law. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer to sell or an offer, or the solicitation of an offer, to acquire or subscribe for shares or other securities issued by the Company, neither by the Company nor by anyone else, in any jurisdiction where such offer or invitation would be illegal under applicable rules or require additional registration or other measures.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the "**Prospectus Regulation**") and has not been approved by any regulatory authority in any jurisdiction. No prospectus has been or will be prepared in connection with the Rights Issue. The Company has prepared and published an information document in the form provided for in Annex IX of the Prospectus Regulation. Within the European Economic Area ("**EEA**"), no public offering of shares is made in a member state other than Sweden. In any other EEA member state, this announcement is only addressed to and is only directed at "qualified investors" in that member state within the meaning of the Prospectus Regulation.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "**Securities Act**"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "**relevant persons**"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release does not identify, or purport to identify, risks (direct or indirect) that may be associated with an investment in new shares. The information contained in this press release is for background purposes for the Rights Issue only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this press release or its accuracy or completeness. Any investment decision to acquire or subscribe for shares in connection with the Rights Issue must be made on the basis of all publicly available information relating to the Company and the Company's shares.

Failure to follow these instructions may result in a breach of the Securities Act or applicable laws in other jurisdictions.

#### *Forward-looking statements*

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this press release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertakes to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or Nasdaq Stockholm's rule book for issuers.

Press Release  
Göteborg June 5, 2026



## Attachments

[IRLAB Bilaga IX Informationsdokument Juni 2026](#)

[IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received](#)